...
【24h】

Does urinary tract infection cause proteinuria or microalbuminuria? A systematic review

机译:尿路感染会引起蛋白尿或微量白蛋白尿吗?系统评价

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Proteinuria, the presence of increased quantities of protein in the urine can be detected by a variety of methods including reagent-strip tests (e.g. Albustix~(TM)), which can be used in a point-of-care testing environment, and chemical tests available in the laboratory. Highly specific immunoassays for specific proteins including albumin are also used. Screening for proteinuria has diagnostic value in the initial detection and confirmation of proteinuric renal disease. Proteinuria is also an important predictor of progressive kidney damage and a potent independent cardiovascular risk marker and predictor. Among patients with suspected or proven chronic kidney disease (CKD), including diabetic nephropathy, reflux nephropathy and early glomerulonephritis, urinalysis for proteinuria is accepted as a useful way of identifying patients at risk of progressive kidney disease. Urinalysis for proteinuria is recommended as part of the initial assessment of patients with hypertension. In people with diabetes mellitus the identification of increased urinary albumin excretion allows the diagnosis of diabetic nephropathy. Microalbuminuria also serves as a risk marker for progressive kidney disease and increased cardiovascular risk, even among non-diabetic individuals. Urinary tract infections (UTIs) are commonly said to be associated with positive results in reagent-strip urinalysis for proteinuria, with some reviews suggesting between 63 and 83% of cases of culture-confirmed UTI having reagent-strip positive tests forprotein. Symptomatic UTIs account for 2-3% of all consultations in general practice and around 6% in the case of women. Asymptomatic UTI is found in approximately 4-7% of pregnant women, 10% of elderly men and 20% of elderly women. Uropathogenic strains of Escherichia coli account for the majority of UTIs that occur in the community.
机译:蛋白尿,尿液中蛋白质含量增加的检测可以通过多种方法进行检测,包括试剂点测试(例如Albustix〜(TM)),可以在现场测试环境中使用,以及化学试剂实验室中可用的测试。还使用了针对特定蛋白(包括白蛋白)的高度特异性免疫测定法。蛋白尿的筛查对蛋白尿性肾病的初步检测和确诊具有诊断价值。蛋白尿还是肾脏进行性损害的重要预测指标,也是独立的有效心血管危险标志和预测指标。在患有可疑或已证实的慢性肾脏病(CKD)的患者中,包括糖尿病性肾病,反流性肾病和早期肾小球性肾炎,尿蛋白分析被认为是识别有进行性肾脏疾病风险的患者的有用方法。建议对蛋白尿进行尿液分析作为高血压患者初步评估的一部分。在糖尿病患者中,尿白蛋白排泄量的增加可以诊断为糖尿病性肾病。微量白蛋白尿也可作为进行性肾脏疾病和心血管疾病风险增加的风险指标,即使在非糖尿病患者中也是如此。尿路感染(UTI)通常被认为与试剂尿样尿蛋白分析阳性结果有关,一些评论表明,在63%至83%的经培养确认的尿道感染病例中,蛋白尿试剂阳性检测结果。有症状的泌尿道感染占一般诊症的2-3%,而女性约占6%。在大约4-7%的孕妇,10%的老年男性和20%的老年女性中发现无症状的尿路感染。大肠埃希氏菌的致病性菌株占该社区中大多数UTI的发生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号